Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.


Tigecycline is the first clinically available semisynthetic glycylcycline approved for clinical use. This study was done to establish a baseline for ongoing surveillance of tigecycline's activity as this agent's clinical use increases. Against 1,796 Staphylococcus aureus (559 multidrug resistant), tigecycline had the lowest minimal inhibitory concentration… (More)
DOI: 10.1159/000118660